Skip to content
Menu

B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $19

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $18 to $19.

B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $18 to $19.

Read at benzinga.com